Lanthanum Carbonate
Pronouncation: (LAN-thah-num CAR-boe-nate)
Class: Phosphate binder
Trade Names:
Fosrenol
- Tablets, chewable 250 mg
- Tablets, chewable 500 mg
Mechanism of Action
Pharmacology
Inhibits GI absorption of phosphate by forming highly insoluble lanthanum phosphate complex with dietary phosphate released from food during digestion.
Pharmacokinetics
Absorption
Very low absorption (bioavailability less than 0.002%). C max is 1 ng/mL.
Distribution
Highly bound to plasma proteins (more than 99%).
Metabolism
Not metabolized and not a substrate of CYP450.
Elimination
Elimination t ½ is 53 h.
Indications and Usage
Reduce serum phosphate in patients with end-stage renal disease.
Contraindications
None known.
Dosage and Administration
Adults
PO Initial dose is 750 to 1,500 mg/day divided and taken with meals. Titrate dose every 2 to 3 wk, generally in increments of 750 mg/day, until acceptable serum phosphate level is reached.
General Advice
- Have patient chew tablets completely before swallowing. Caution patient not to swallow intact tablets.
- In order to bind dietary phosphate efficiently, administer prescribed dose with or immediately after a meal.
Storage/Stability
Store tablets at controlled room temperature (59° to 86°F). Protect from moisture.
Drug Interactions
Compounds known to interact with antacids
Do not take within 2 h of lanthanum.
Laboratory Test Interactions
None well documented.
Adverse Reactions
Cardiovascular
Hypotension (at least 5%).
CNS
Headache (at least 5%).
EENT
Rhinitis (at least 5%).
GI
Abdominal pain, constipation, diarrhea, nausea, vomiting (at least 5%).
Metabolic-Nutritional
Hypercalcemia (at least 5%).
Respiratory
Bronchitis (at least 5%).
Miscellaneous
Dialysis graft occlusion or complication (at least 5%).
Precautions
Pregnancy
Category C .
Lactation
Undetermined.
Children
Not recommended.
Special Risk Patients
Use with caution in patients with acute peptic ulcer, ulcerative colitis, Crohn disease, or bowel obstruction because these populations were not included in clinical studies.
Patient Information
- Advise patient that medication does not replace diet changes and to continue to adhere to prescribed diet.
- Advise patient that dose may be adjusted periodically in order to achieve maximum benefit.
- Advise patient to take each dose with or immediately after a meal. Caution patient to chew tablets thoroughly before swallowing and not to swallow intact tablets.
Recent Drug Updates at Web Drug List
ElixSure Cough Gel Syrup
Helixate recombinant
Idenal with Codeine
Kayexalate
Lexxel
Lisinopril
MDP
Novo-Naprox
Oxy Balance Emergency Spot Treatment Invisible Formula Gel Topical
physostigmine ophthalmic
|